Disruptive Technologies in Pharma 2020

SMi Group 20 - 21 January 2020, London, UK.
The conference aims to bring together experts of emerging technologies to discover the opportunities with regards to Artificial intelligence, Machine Learning, Internet of Things, Digital therapeutics, eHealth and blockchain. The effect of these technologies on the industry will be discussed with the aim to highlight challenges related to the implementation of these new technologies and to discuss how to overcome them.

Industry case studies will reveal personal experiences and strategies to approaching digitalization, providing a benchmark for practice and improving understanding of forecasts until 2020.

Transformations require regulatory adjustments therefore, the conference will also feature insights into new regulatory guidelines and standards of practice, with special focus on the new class of drugs called digital therapeutics, to provide a complete picture of every aspect of the transformation process.

Network and learn from leading professionals such as Vice Presidents, Directors Managers and Heads of: Emerging/Disruptive Technologies, Artificial Intelligence, Machine Learning, Data Science/Analytics, Technology, External and Internal Innovation, Digital IoT and Bioinformatics.

Chairs for 2020

  • Karl Hess, Managing Director, OnDigitalHealth Consulting

Featured Speakers include

  • Mark Campbell, Freelance Regulatory Expert, former NICE
  • Vladimir Anisimov, Principal Data Scientist, Amgen
  • Joseph Dalton, Global Lead Digital Health Solutions and Medical Outcomes, Novartis

For more information and to register, plase visit www.disruptivetech-pharma.com/WPN

About SMi Group

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network.

Most Popular Now

Positive Phase 1 data from mRNA-based individualiz…

BioNTech SE (Nasdaq: BNTX, "BioNTech") announced initial data from an ongoing investigator-initiated first-in-human Phase 1 study evaluating the safety and tolerability o...

FDA approves RIABNI™ (rituximab-arrx), a biosimila…

Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved RIABNI™ (rituximab-arrx), a biosimilar to Rituxan®, in combination with ...

Pfizer to invest $120 million to produce COVID-19 …

Pfizer Inc. (NYSE: PFE) announced today that it will further strengthen its commitment to United States manufacturing with a $120 million investment at its Kalamazoo, Mic...

Proteomic study of 2,002 tumors identifies 11 pan-…

A new study that analyzed protein levels in 2,002 primary tumors from 14 tissue-based cancer types identified 11 distinct molecular subtypes, providing systematic knowled...

A new technology offers treatment for HIV infectio…

A new study from Tel Aviv University offers a new and unique treatment for AIDS which may be developed into a vaccine or a one time treatment for patients with HIV. The s...

Sanoff offers perspective on a promising rectal ca…

UNC Lineberger Comprehensive Cancer Center's Hanna K. Sanoff, MD, MPH, is the author of a viewpoint in the New England Journal of Medicine that provides a perspective on ...

Broadly neutralizing antibodies could provide immu…

Two broadly neutralizing antibodies show great promise to provide long-acting immunity against COVID-19 in immunocompromised populations according to a paper published Ju...

Boehringer Ingelheim signs option to acquire Truti…

Boehringer Ingelheim announced the signing of an option to acquire Trutino Biosciences Inc. (the "Transaction"), a San Diego-based biotech company. Trutino Biosciences...

Novel drug combo activates natural killer cell imm…

Most skin cancer drugs that activate the immune system work by triggering immune cells, called T cells, to attack tumors, but when T cells are activated for too long, the...

Novartis announces Nature Medicine publication of …

Novartis announced that Nature Medicine published final results from both the two- and three-copy cohorts of the completed Phase 3 SPR1NT trial as separate companion manu...

COVID-19 rebound after taking Paxlovid likely due …

Paxlovid is the leading oral medication for preventing severe cases of COVID-19 in high-risk individuals. However, symptoms returned in some patients after treatment was ...

Biomarkers found that could be drug targets agains…

Biomarkers that could be targets for novel drugs to treat glioblastoma brain tumors have been identified by investigators at Georgetown Lombardi Comprehensive Cancer Cent...